ロード中...
Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
Introduction: China has ~6 million patients with active epilepsy every year, around 60% of whom suffer from partial-onset seizures. Perampanel (PER) is a novel anti-epileptic drug for partial-onset seizures. PER has been included in the latest Chinese National Reimbursement Drug List (NRDL) in 2020....
保存先:
| 出版年: | Front Public Health |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8290415/ https://ncbi.nlm.nih.gov/pubmed/34295868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fpubh.2021.670108 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|